MEP39308A - Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method - Google Patents

Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Info

Publication number
MEP39308A
MEP39308A MEP-393/08A MEP39308A MEP39308A ME P39308 A MEP39308 A ME P39308A ME P39308 A MEP39308 A ME P39308A ME P39308 A MEP39308 A ME P39308A
Authority
ME
Montenegro
Prior art keywords
substance
subcutaneous dose
fsh
substances
amount equivalent
Prior art date
Application number
MEP-393/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Evert Johannes Bunschoten
Bennink Herman Jan Tijmen Coelingh
Original Assignee
Ares Trading S A Chateau De Vaumarcus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S A Chateau De Vaumarcus filed Critical Ares Trading S A Chateau De Vaumarcus
Publication of MEP39308A publication Critical patent/MEP39308A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-393/08A 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method MEP39308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077221 2002-06-07
PCT/NL2003/000370 WO2003103770A2 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Publications (1)

Publication Number Publication Date
MEP39308A true MEP39308A (en) 2011-02-10

Family

ID=29724462

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-393/08A MEP39308A (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Country Status (21)

Country Link
US (1) US7815912B2 (es)
EP (1) EP1511537B1 (es)
JP (1) JP2005530818A (es)
KR (1) KR20050058285A (es)
CN (1) CN1684737A (es)
AU (1) AU2003274929B2 (es)
BR (1) BR0305033A (es)
CA (1) CA2488719A1 (es)
EA (1) EA009371B1 (es)
ES (1) ES2399962T3 (es)
IL (1) IL165522A0 (es)
IS (1) IS7586A (es)
ME (1) MEP39308A (es)
MX (1) MXPA04012246A (es)
NO (1) NO20045304L (es)
NZ (1) NZ536984A (es)
PL (1) PL373991A1 (es)
RS (1) RS105004A (es)
UA (1) UA81251C2 (es)
WO (1) WO2003103770A2 (es)
ZA (1) ZA200409857B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583363B (zh) * 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
BR112014001274A2 (pt) 2011-07-18 2017-04-18 Arts Biologics As composto de hormônio luteinizante, e, composição farmacêutica
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
US9216037B2 (en) 2013-06-21 2015-12-22 Previvo Genetics, Llc Uterine lavage for embryo retrieval
US9282995B2 (en) * 2011-12-22 2016-03-15 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
AU2021218895A1 (en) 2020-02-10 2022-09-15 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
WO2026018221A1 (en) 2024-07-18 2026-01-22 ReproNovo SA Crystalline compositions for improving embryo implantation and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0788799A3 (en) * 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
CN1199642A (zh) * 1997-05-16 1998-11-25 Asta药物股份公司 治疗不育症的lhrh-拮抗剂
ES2247710T3 (es) 1997-06-20 2006-03-01 Akzo Nobel N.V. Antagonista de gonadotropina.
CZ301912B6 (cs) * 1998-04-23 2010-07-28 Zentaris Ivf Gmbh Lécivo na lécení neplodnosti nitrodeložní inseminací
CN1353617A (zh) * 1999-02-24 2002-06-12 诺沃挪第克公司 不孕症的治疗
US20030092628A1 (en) * 1999-06-23 2003-05-15 De Greef Henrik Johan Matthieu Maria Gonadotropin releasing hormone antagonist
AU6263800A (en) * 1999-06-23 2001-01-31 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
MEP38808A (en) * 2001-09-12 2011-02-10 Merck Serono Sa Use of lh in controlled ovarian hyperstimulation
ATE376839T1 (de) 2001-12-21 2007-11-15 Pantarhei Bioscience Bv Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutisches kit zur verwendung in diesem verfahren

Also Published As

Publication number Publication date
NO20045304L (no) 2005-02-07
BR0305033A (pt) 2004-11-09
ES2399962T3 (es) 2013-04-04
CA2488719A1 (en) 2003-12-18
EA009371B1 (ru) 2007-12-28
CN1684737A (zh) 2005-10-19
AU2003274929A1 (en) 2003-12-22
US7815912B2 (en) 2010-10-19
AU2003274929B2 (en) 2008-04-10
EA200401619A1 (ru) 2005-06-30
WO2003103770A2 (en) 2003-12-18
IL165522A0 (en) 2006-01-15
US20050235374A1 (en) 2005-10-20
UA81251C2 (en) 2007-12-25
MXPA04012246A (es) 2005-04-08
RS105004A (sr) 2007-02-05
EP1511537A2 (en) 2005-03-09
PL373991A1 (en) 2005-09-19
NZ536984A (en) 2008-01-31
KR20050058285A (ko) 2005-06-16
EP1511537B1 (en) 2012-11-21
IS7586A (is) 2004-12-03
WO2003103770A3 (en) 2004-04-22
ZA200409857B (en) 2006-02-22
JP2005530818A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
Emons et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
Schneider et al. Estradiol and the neuroendocrine control of LH release in vitro
Huirne et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study
AR011217A1 (es) UN PÉPTIDO ANTAGONISTA DE GNRH, UNA COMPOSICIoN FARMACÉUTICA PARA INHIBIR LA SECRECIoN DE GONADOTROPINAS EN MAMíFEROS Y UN COMPUESTO INTERMEDIARIO PARA PREPARAR UN PÉPTIDO ANTAGONISTA DE GNRH.
ROSEMBERG et al. Clinical effect of human urinary postmenopausal gonadotropin
Wilcox et al. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies
Thomas et al. Principles of endocrine pharmacology
RU2005136527A (ru) Унитарная комбинация fsh и hcg
KR950703359A (ko) 임신치료를 위한 파라소면(parathormone), 그 생물학적 활성 프래그먼트(fragment) 및 관련 펩티드(peptide)의 용도
EA200401619A1 (ru) Способ управляемой гиперстимуляции яичников и фармацевтический набор для использования в таком способе
EA001178B1 (ru) Применение lhrh-аналога или комбинации lhrh-аналогов и антиэстрогена с селективным по отношению к тканям эстрогенным действием для лечения гинекологических нарушений
Gerris et al. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 μg), GnRH agonist (buserelin, 500 μg) and human chorionic gonadotrophin (10 000 IU)
Reichman et al. GnRH antagonist-based protocols for in vitro fertilization
Tur-Kaspa et al. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
WO2005018657A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
MXPA03009447A (es) Inhibidor de aromatasa de dosis unica para tratamiento de infertilidad.
WO2005019457A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
WO1990014839A1 (en) A process for treating infertility and an agent for use in the process
KR20030051828A (ko) 에스트로겐 의존성 질환의 병용 치료법
BR9611760A (pt) Novos antagonistas lh-rh com efeito aperfeiçoado
Curry Alterations in incidence of mating and copulation-induced ovulation after olfactory bulb ablation in female rats
Bretzlaff Physiology and pharmacology of the postpartum cow and retained fetal membranes
Daya GnRH antagonists in assisted reproduction
Engel et al. Luteinizing hormone-releasing hormone antagonists in gynecology